***Background.*** The LEADER Program has monitored the activity of linezolid (LZD) and comparator agents in USA medical centers since 2004. The percent of non-susceptible (NS) Gram-positive (GP) monitored isolates has remained below 1% (range, 0.14-0.45%; 0.17% in 2012).

***Methods.*** In 2013, a total of 7,183 GP pathogens were sampled from 60 medical centers across the USA. Isolates were susceptibility (S) tested by CLSI reference broth microdilution methods. LZD NS isolates were confirmed by repeated reference S testing, with the LZD Etest (bioMerieux, Hazelwood, Missouri) and CLSI disk diffusion methods.

***Results.*** A total of 3,035 *S. aureus* strains were submitted. Methicillin-resistant *S. aureus* (MRSA; 47.9%) varied from 35.1% (Middle Atlantic) to 58.7% (East South Central). Resistance rates among MRSA for many antimicrobial agents were much higher than in MSSA. Examples included the β-lactam agents, levofloxacin (MRSA, 64.2%, MSSA, 11.2%), clindamycin (26.7%, 5.3%), and erythromycin (87.8%, 31.9%). The LZD MIC~50/90~ for *S. aureus* was 1/1 µg/ml (S, 99.9%). There were two LZD NS isolates (MRSA from California and Michigan); both contained *cfr* and L3 mutations. The MIC~50~ and modal MIC for MRSA and MSSA were the same. A total of 580 CoNS isolates exhibited a LZD MIC~50/90~ at 0.5/1 µg/ml (S, 99.5%). The three LZD NS CoNS isolates contained mutations at 23S rRNA and L3 and/or L4. LZD was active against Enterococci with a MIC~50/90~ at 1/1 µg/ml and 99.4% S. All LZD NS enterococci had a G2476T mutation and one also contained a *cfr*. S to LZD for 399 viridans group streptococci (VGS) and 964 β-hemolytic streptococci was 99.7 and 100.0%, respectively. There was one *S. sanguinis* isolate (LZD NS \[MIC, 4 µg/ml\]), which demonstrated a mutation at the G2576 nucleotide of the 23S rRNA. LZD S for all organisms tested (7,183) was 99.83% with only 12 isolates (6 Enterococci, 2 *S. aureus*,3 *S. epidermidis,* 1 VGS) testing NS.

***Conclusion.*** LZD among USA medical centers demonstrated excellent activity and a sustained S rate of 99.83%. LZD MIC population distributions remain stable without evidence of "MIC creep" among monitored species. These data show no evidence of widespread dissemination of the *cfr* resistance determinant in LEADER Program monitored USA medical centers.
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